Loading clinical trials...
Loading clinical trials...
Browse 661 clinical trials for schizophrenia. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 21-40 of 661 trials
NCT06939088
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD). This study aims to investigate whether the Glucose-dependent Insulinotropic Polypeptide/GLP-1RA tirzepatide will reduce alcohol consumption in patients with a dual diagnosis of AUD and schizophrenia, a population in dire need of improved treatment options. To further investigate the neurobiological underpinnings of a potential dampening effect on alcohol consumption, functional magnetic resonance imaging (fMRI) brain scans will be applied. The key anticipated outcomes include: * decreased alcohol consumption and * reduced alcohol cue-induced brain activity in the GIP/GLP-1-treated patient group compared with the placebo group. To the best of the investigators knowledge, this has never been examined before.
NCT02167724
The aim of this study is to know the bucco-dental status of patients with schizophrenia in Côte d'Or. Participation in this study will last only as long as it takes to: * carry out a bucco-dental examination: evaluation of dental plaque and calculus * take a blood sample to assess needs in vitamin C (only for patients included at DIJON CHU and CHS Chartreuse) * complete a 30-minute questionnaire: clinical data and answers to questions concerning dental hygiene and eating habits.